Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter M Irving

Showing results (21-30 of 194) with videos related to

Pageof 20
Sort By:
European Journal of Gastroenterology & Hepatology|September 19, 2023
JAK inhibitors for the treatment of inflammatory bowel disease: results of an international survey of perceptions, attitudes, and clinical practiceSailish Honap, Peter M Irving, Mark A Samaan
Gut|February 21, 2020
New role for azathioprine in case of switching anti-TNFs in IBDKonstantinos Papamichael, Adam S Cheifetz, Peter M Irving
Journal of Crohn'S & Colitis|August 12, 2022
Ustekinumab-Induced Inflammatory Demyelinating Polyneuropathy in a Patient with Ulcerative ColitisSailish Honap, Peter M Irving, Mark A Samaan
Gut|November 20, 2020
COVID-19 and IBD drugs: should we change anything at the moment?Charlie W Lees, Peter M Irving, Laurent Beaugerie
Journal of Crohn'S & Colitis|June 14, 2021
Response to 'Clinical Efficacy of Tofacitinib in Moderate to Severe Ulcerative Colitis'Sailish Honap, Peter M Irving, Nicholas A Kennedy
Alimentary Pharmacology & Therapeutics|July 31, 2019
Letter: immune checkpoint inhibitor-induced colitis-shouldn't we be checking more often?Mark A Samaan, Nick Powell, Peter M Irving
The American Journal of Gastroenterology|December 14, 2007
Drug interactions in inflammatory bowel diseasePeter M Irving, Fergus Shanahan, David S Rampton
Alimentary Pharmacology & Therapeutics|August 22, 2022
Review article: guide to tofacitinib dosing in patients with ulcerative colitisPeter M Irving, Yvette Leung, Marla C Dubinsky
World Journal of Gastroenterology|November 4, 2015
How should immunomodulators be optimized when used as combination therapy with anti-tumor necrosis factor agents in the management of inflammatory bowel disease?Mark G Ward, Peter M Irving, Miles P Sparrow
Digestive Diseases and Sciences|August 25, 2020
Vedolizumab Dose Escalation: In for a Penny, in for a Pound?Robin J Dart, Peter M Irving, Mark A Samaan
Pageof 20

Showing results (21-30 of 194) with videos related to

Sort By:
Pageof 20
European Journal of Gastroenterology & Hepatology|September 19, 2023
JAK inhibitors for the treatment of inflammatory bowel disease: results of an international survey of perceptions, attitudes, and clinical practiceSailish Honap, Peter M Irving, Mark A Samaan
Gut|February 21, 2020
New role for azathioprine in case of switching anti-TNFs in IBDKonstantinos Papamichael, Adam S Cheifetz, Peter M Irving
Journal of Crohn'S & Colitis|August 12, 2022
Ustekinumab-Induced Inflammatory Demyelinating Polyneuropathy in a Patient with Ulcerative ColitisSailish Honap, Peter M Irving, Mark A Samaan
Gut|November 20, 2020
COVID-19 and IBD drugs: should we change anything at the moment?Charlie W Lees, Peter M Irving, Laurent Beaugerie
Journal of Crohn'S & Colitis|June 14, 2021
Response to 'Clinical Efficacy of Tofacitinib in Moderate to Severe Ulcerative Colitis'Sailish Honap, Peter M Irving, Nicholas A Kennedy
Alimentary Pharmacology & Therapeutics|July 31, 2019
Letter: immune checkpoint inhibitor-induced colitis-shouldn't we be checking more often?Mark A Samaan, Nick Powell, Peter M Irving
The American Journal of Gastroenterology|December 14, 2007
Drug interactions in inflammatory bowel diseasePeter M Irving, Fergus Shanahan, David S Rampton
Alimentary Pharmacology & Therapeutics|August 22, 2022
Review article: guide to tofacitinib dosing in patients with ulcerative colitisPeter M Irving, Yvette Leung, Marla C Dubinsky
World Journal of Gastroenterology|November 4, 2015
How should immunomodulators be optimized when used as combination therapy with anti-tumor necrosis factor agents in the management of inflammatory bowel disease?Mark G Ward, Peter M Irving, Miles P Sparrow
Digestive Diseases and Sciences|August 25, 2020
Vedolizumab Dose Escalation: In for a Penny, in for a Pound?Robin J Dart, Peter M Irving, Mark A Samaan
Pageof 20